Explore the latest books of this year!
Bookbot

Bad Blood

Book rating

More about the book

"In 2014 Theranos founder and CEO Elizabeth Holmes was widely seen as the female Steve Jobs: a brilliant Stanford dropout whose startup 'unicorn' promised to revolutionize the medical industry with a machine that would make blood tests significantly faster and easier ... There was just one problem: The technology didn't work. For years, Holmes had been misleading investors, FDA officials, and her own employees. When [the author], working at The Wall Street Journal, got a tip from a former Theranos employee and started asking questions, both [he] and the Journal were threatened with lawsuits. Undaunted, the newspaper ran the first of dozens of Theranos articles in late 2015. By early 2017, the company's value was zero and Holmes faced potential legal action from the government and her investors. Here is the riveting story of the biggest corporate fraud since Enron, a disturbing cautionary tale set amid the bold promises and gold-rush frenzy of Silicon Valley"--

Book purchase

Bad Blood, John Carreyrou

Language
Released
2020
product-detail.submit-box.info.binding
(Paperback)
No longer available.
or
View available edition

Payment methods

4.5
Very Good
1347 Ratings

We’re missing your review here.

Language
English
Released
2020
Format
Paperback
ISBN10
0593081641
ISBN13
9780593081648
Series
First published
2018
Original title
Bad Blood: Secrets and Lies in a Silicon Valley Startup
Rating
4.45 out of 5
Description
"In 2014 Theranos founder and CEO Elizabeth Holmes was widely seen as the female Steve Jobs: a brilliant Stanford dropout whose startup 'unicorn' promised to revolutionize the medical industry with a machine that would make blood tests significantly faster and easier ... There was just one problem: The technology didn't work. For years, Holmes had been misleading investors, FDA officials, and her own employees. When [the author], working at The Wall Street Journal, got a tip from a former Theranos employee and started asking questions, both [he] and the Journal were threatened with lawsuits. Undaunted, the newspaper ran the first of dozens of Theranos articles in late 2015. By early 2017, the company's value was zero and Holmes faced potential legal action from the government and her investors. Here is the riveting story of the biggest corporate fraud since Enron, a disturbing cautionary tale set amid the bold promises and gold-rush frenzy of Silicon Valley"--